Strong Buy
Buy
Hold
Sell
Strong Sell
Consensus
| Date | Grading Company | New Grade | Previous Grade | Action | Price When Posted | News Title | Publisher |
|---|---|---|---|---|---|---|---|
| 2025-12-01 | RBC Capital | Outperform | Sector Perform | Upgrade | $2.24 | Neumora Therapeutics upgraded to Outperform from Sector Per… | TheFly |
| 2025-10-28 | Needham | Buy | Buy | Hold | $2.675 | Neumora Therapeutics price target raised to $8 from $6 at N… | TheFly |
| 2025-10-27 | Guggenheim | Buy | Neutral | Upgrade | $2.63 | Neumora Therapeutics upgraded to Buy from Neutral at Guggen… | TheFly |
| 2025-03-07 | William Blair | Market Perform | Outperform | Downgrade | $1.49 | Neumora Therapeutics downgraded to Market Perform from Outp… | TheFly |
| 2025-03-07 | Guggenheim | Neutral | N/A | Downgrade | $1.49 | Neumora Therapeutics downgraded to Neutral from Buy at Gugg… | TheFly |
| 2025-01-02 | RBC Capital | Sector Perform | Outperform | Downgrade | $1.97 | RBC downgrades Neumora Therapeutics to Sector Perform after… | TheFly |
| 2024-10-01 | H.C. Wainwright | Buy | N/A | Initialise | $13.21 | Neumora Therapeutics initiated with a Buy at H.C. Wainwright | TheFly |
| 2024-07-22 | Needham | Buy | N/A | Initialise | $11.28 | Neumora Therapeutics initiated with a Buy at Needham | TheFly |
| 2024-06-17 | RBC Capital | Outperform | Outperform | Hold | $9.71 | RBC Capital Reiterates Outperform Rating on Neumora Therape… | StreetInsider |
| 2023-10-10 | RBC Capital | Outperform | N/A | Initialise | $10.94 | Why Neumora Therapeutics Analysts Are Bullish About Major D… | Benzinga |